FDA Is Investigating If Sarepta’s Gene Therapy Should Stay on Market

FDA commissioner Martin Makary

Photographer: Annabelle Gordon/Bloomberg

US Food and Drug Administration Commissioner Marty Makary said he’s “taking a hard look” at whether a gene therapy from Sarepta Therapeutics Inc. should remain on the market.

Makary made the comments in an interview with Bloomberg News.